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Background/aim: Metabolomics has the potential to provide putative biomarkers and insights into the pathophysiology and
diagnosis of pediatric multiple sclerosis (pMS), which is an inflammatory demyelinating disorder of the central nervous system with
a broad spectrum of clinical manifestations. In this study, we aimed to investigate serum metabolomics in pMS to help elucidate the
pathophysiology of MS.
Materials and methods: An untargeted approach was applied using the quadrupole time-of-flight liquid chromatography/mass spectrometry
(Q-TOF LC/MS) method to study plasma metabolites in patients with pMS (n = 33), patients with unclassified central nervous system
demyelinating diseases (n = 6), and age-matched healthy control subjects (n = 40). The patient and control groups were compared for
metabolites and the normalized peak areas differed statistically (p < 0.05), showing at least a 1.25-fold change between groups. Bioinformatic
tools combined with a clinical perspective were employed for the identification of the putative metabolites. In addition to the untargeted
metabolomics approach, targeted LC-MS/MS metabolite analysis was employed to compare the pMS group with the control group.
Results: Significant differences between the patient and control groups were noted for tyramine, 4-hydroxyphenylacetaldehyde,
sphingosine/3-dehydrosphinganine, prostaglandins/thromboxane A2, 20-hydroxy-leukotriene E4, 3α,7α,12α-trihydroxy-5β-cholestan26-al/calcitriol, pantetheine, ketoleucine/3-methyl-2-oxovaleric acid, L-arginine/D-arginine, coproporphyrinogen III, (S)-reticuline,
carnosine, cytidine, and phosphoribosyl pyrophosphate. Additional tests for sphingosine 1-phosphate, sphingophosphocholines,
ceramides, oxysterols, and calcitriol levels yielded significant metabolomic differences for the pMS group compared to the control group.
The metabolomic data of 3/6 patients with unclassified demyelinating disorders matched the pMS group; their follow-up verified the
diagnosis of pMS.
Conclusion: In general, plasma metabolites related to sphingolipid metabolism, myelin products, inflammatory pathways, mitochondrial
dysfunction, and oxidative stress were found to be altered in cases of pMS. The method applied in this study, combining untargeted
analysis with a targeted approach, can be applied to larger series of cases of pMS and other demyelinating disorders for further validation.
Key words: Metabolomics, quadrupole time-of-flight liquid chromatography/mass spectrometry, biomarker, pediatric multiple
sclerosis, diagnosis

1. Introduction
Multiple sclerosis (MS) can present with a wide range of
neurological symptoms. Its diagnosis is based on clinical
evaluation, magnetic resonance imaging (MRI), and
cerebrospinal fluid (CSF) analysis. Pediatric multiple
sclerosis (pMS) is defined by the first attack occurring
before 18 years of age. It constitutes up to 10% of all MS
cases and its prevalence ranges between 0.13 and 0.66 per

100,000 children per year [1]. Its differential diagnosis
from other inflammatory demyelinating diseases can be
difficult and many cases that do not meet the diagnostic
criteria of the International Pediatric Multiple Sclerosis
Group (IPMSSG) [2] remain unclear. Disease-related
biomarkers might assist in such cases and may also
provide information on the pathogenesis, treatment, and
prognosis of the disease.
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Metabolomics is a powerful tool in the investigation of
putative biomarkers. It entails the dynamic, comprehensive,
large-scale analysis of small molecules downstream of the
proteome and, therefore, closer to the phenotype of an
organism in comparison to genomics, transcriptomics, or
proteomics. The metabolome comprises more than 15,000
endogenous metabolites affected by diseases. Although no
technique is capable of analyzing the whole metabolome
with a single injection, metabolomic research techniques for
sample preparation, analysis, computerized interpretation,
and data banks are constantly being improved [3].
The Human Metabolome Database (HMDB,
www.hmdb.ca) is a web-enabled database containing
comprehensive information about human metabolites and
their biological roles, physiological concentrations, disease
associations, chemical reactions, metabolic pathways,
reference spectra, interactions with single-nucleotide
polymorphisms, and the effects of drugs on these
metabolites. In the last decade, the HMDB was expanded
from 6408 to 114,100 metabolites (http://www.hmdb.ca/
statistics) and it is now considered the standard resource
for human metabolomic studies [3]. Databases allow
the interpretation of untargeted metabolomic studies
using advanced analytical techniques such as quadrupole
time-of-flight liquid chromatography/mass spectrometry
(Q-TOF LC/MS). However, a limitation of untargeted
studies is the possibility of one mass/charge (m/z) ratio
matching with more than one metabolite. Such situations
can be overcome with recent data-mining strategies using
platforms like MetaboAnalyst, which allow users to match
the final m/z list of the peaks with metabolites logically
using pathway analysis [4]. Furthermore, examining the
final data from a clinical perspective can be useful for
disregarding irrelevant results.
In this study, plasma samples of patients with pMS
diagnosed according to clinical and radiological criteria,
patients with unclassified central nervous system (CNS)
demyelinating diseases, and healthy control subjects were
studied. An untargeted Q-TOF LC/MS metabolomics
approach and, where applicable, a targeted LC-MS/MS
approach were applied to elucidate metabolites specific
to pMS. The raw data of the untargeted study [5] were
processed with MetaboAnalyst. The results were examined
for metabolites likely to be involved in the pathogenesis of
the disease. This is one of the first metabolomic studies of
pMS using this approach.
2. Materials and methods
2.1. Study population and sample collection
This research was undertaken with a single-center,
prospective design. The diagnosis of pMS was made
according to IPMSSG criteria [2]. Patients with pMS
(Group pMS, n = 33), patients with an unclassified CNS
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demyelinating disorder not matching the diagnostic
criteria of pMS [Group unknown (Group U), n = 6], and
a control group (Group C, n = 40) in which inflammatory
demyelinating disorders ruled out were included in the
study. Sampling was done when patients came to routine
control visits or were hospitalized during an attack.
Those in Group pMS who received beta interferon
(β-IFN) treatment were divided into two subgroups to
evaluate the metabolomic differentiation between relapse
and remission periods as Group pMS-T1 and Group
pMS-T2. Sampling for Group pMS-T1 (n = 10) was done
in the remission period, while for Group pMS-T2 (n = 5),
sampling was done in the relapse period [not all patients
with pMS who received β-IFN (n = 20) could be included
in Group pMS-T1 or Group pMS-T2]. Since pooled
samples were used to compare the pMS and control
groups, individual plasma samples of pMS patients were
selected randomly from among the pooled pMS samples
to form Group Random (Group R, n = 6) to verify
whether the pooled pMS samples represented the pMS
metabolome. This internal control process was verified
using principal component analysis (PCA) graphs.
Demographic and clinical data are summarized in Table
1. All patients and control subjects were examined in the
Hacettepe University, Faculty of Medicine’s Department
of Pediatric Neurology. Informed consent from all
patients and parents and ethical approval from the
institution (2019/21-06) were obtained.
2.2. Preparation of the samples
Plasma was separated from 3 mL of peripheral venous
blood from each participant and withdrawn into tubes
containing ethylenediaminetetraacetic acid (3000 rpm,
10 min). The plasma samples were held at –80 °C until
analysis. Stored samples were thawed on the day of the
experiment and 200 µL of plasma from each patient
from Group pMS including both pMS-T1 and pMS-T2
were pooled in conical Falcon tubes of 15 mL (Fisher
Scientific, Portsmouth, NH, USA) and vortexed. Samples
from Group C were pooled in the same way. The samples
from Group R and Group U were prepared as individual
samples. All pooled and individual samples were
subjected to metabolite extraction by nanofiltration using
ultrafiltration cartridges (3 kDa pores, Amicon Ultra 0.5
mL Centrifugal Filters, Merck, Darmstadt, Germany), and
300 µL of sample and 150 µL of acetonitrile were placed
into a cartridge and centrifuged (15,000 rpm, 45 min). The
filtered liquid (metabolite phase) was collected and dried
with a vacuum centrifuge (9 °C, Labconco CentriVap
Benchtop Vacuum Concentrator, Kansas City, MO, USA),
then dissolved with acetonitrile and water (300 µL, 1:1
v/v). All solvents were of LC-MS grade (Sigma-Aldrich,
St. Louis, MO, USA). Pooled samples of Group pMS and
Group C were subjected to consecutive dilutions (dilution
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factors: 4:4, 4:4, 4:4, 3:4, 2:4, 1:4 v/v) as described in the
literature to process the data statistically and prevent falsepositive peaks [6]. Figure 1 illustrates the steps of sample
collection and preparation.
2.3. Untargeted and targeted metabolomics
2.3.1. Q-TOF LC/MS analyses
The experiments were performed on an Agilent 6530
LC/MS Q-TOF instrument (Agilent Technologies, Santa
Clara, CA, USA) using a C18 column (Agilent Zorbax
1.8 µM, 50.0×2.1 mm). Mobile phases (acetonitrile:water,
0.1% formic acid) were subjected to a flow of 0.20 mL
min–1 that began with 90% H2O until the end of the 1st
min and then the acetonitrile ratio was increased linearly
to 90% by the 15th min. The chromatographic conditions
were then linearly returned to the starting conditions by
the 20th min and a 5–min post-run was applied for further
injections. The aim of using this gradient elution program
was to separate both polar and nonpolar metabolites
properly under the selected chromatographic conditions.
The scan range for the MS device was 100–1700 m/z. All
samples were injected as two replicates in random order.
The column temperature was 30 °C and capillary voltage
was 4000 V. The mass spectrometer, equipped with an
ESI probe, was operated in positive (ESI+) ion mode
using the standards recommended by the manufacturer
for the device. System suitability for LC separation and
MS detection was measured using quality control (QC)
samples (Waters Co., LC/MS QC Reference Standard
[186006963]), which were injected before the analysis.
Injection repeatability was checked with retention time and
peak intensity shifts. The reproducible chromatographic
conditions allowed the performance of all experiments
under identical conditions.

2.3.2. Data processing
Raw chromatograms for all groups were processed with
XCMS using parameters optimized with the Isotopologue
Parameter Optimization (IPO) tool [7]. A normalization
procedure was performed before the statistical comparison
of groups. False-positive peaks were eliminated from pooled
samples (Group pMS and Group C) with the application of
recently introduced data processing strategies including a
consecutive dilution technique to eliminate false-positive
peaks and peak normalization to discard random errors
from peak areas [6]. Peaks normalized using the total
area of all peaks were compared among themselves and
the peaks with significant differences (p < 0.05) and fold
change values of >1.25 between Groups pMS and C were
statistically compared with the individual samples (Groups
U and R). Normalizations and comparisons of peak areas
were performed with MS Excel and t-tests were used for
statistical comparison. The MS Peaks to Pathways utility of
MetaboAnalyst 4.0 was used to match the final list of peaks
with Kyoto Encyclopedia of Genes and Genomes (KEGG)
codes to identify potential biomarkers, which were then
reviewed with a clinical evaluation using a detailed
literature search to associate the results with the pathology
of the disease. In addition, the results were visualized
using two-dimensional PCA score plots, as is commonly
done for large volumes of data from high-throughput
metabolomics experiments.
2.3.3. LC-MS/MS analyses
In addition to the untargeted metabolomics approach,
some potential biomarkers related to putative metabolites
found in untargeted analysis were also measured with a
targeted approach. Sphingosine 1-phosphate, long-chain
(16–20) and very long-chain (22–24) ceramide, and

Figure 1. An illustration of sample collection and preparation.
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Table 1. Demographic data and distribution of groups.
Group pMS
(n = 33)

Group U
(n = 6)

Group C
(n = 40)

Group T
(n = 15)

Group pMS-T1
(n = 10)

Group pMS-T2
(n = 5)

Gender

26F, 7M

3F, 3M

31F, 9M

12F, 3M

8F, 2M

4F, 1M

Age at blood
sampling (years)

16.4 ± 2.7
(range: 11–22,
median: 17)

12.1 ± 4.9
(range: 3–16,
median: 14.5)

16.2 ± 2.7
(range: 9–22,
median: 16.5)

16.5±2
(range: 13–19)

17.4 ± 1.6
(range: 14–19)

14.8 ± 1.6
(range: 13–17)

Age at diagnosis

13 ± 2.7
(range: 4–17,
median: 14)

12.8 ± 4.7
(range: 4–16,
median: 15)

13.2 ± 3
(range: 4–17,
median: 14)

13.7 ± 1.8
(range: 10–17,
median: 13.5)

12.2 ± 4.9
(range: 4–17,
median: 14)

Time from
diagnosis to
blood sampling
(years)

3.5 ± 2.6
(range: 0.5–10,
median: 4)

1.1 ± 0.2
(range: 1–1.5,
median: 1)

3.5 ± 2.6
(range: 0.5–10,
median: 4)

3.7 ± 1.6
(range: 1–6,
median: 4)

3.1 ± 4.1
(range: 0.5–10,
median: 0.5)

Oligoclonal band
positivity

26/29 (89.6%)

4/6 (33%)

8/33 patients (24%) within
Attack status at the
4/6 within a
a week of relapse (3/8
time of sampling
week of the
under treatment); others in
episode
remission under treatment

Treatment

β-IFN:20, GA:1, Fg:4,
DMF:4, NTZ:1, TRF:1,
NT:2

None

All within a
week of the
episode

-

-

β-IFN

β-IFN

β-IFN

Abbreviations: Group pMS: Group with pediatric multiple sclerosis, Group U: Group with unknown diagnosis, Group C: Control
group, Group T: 15 of 20 patients receiving β-IFN (Group T: Group pMS-T1 plus Group pMS-T2), Group pMS-T1: 10 patients in
remission from Group pMS-T who received β-IFN, Group pMS-T2: 5 patients from group pMS-T who received β-IFN and were
in relapse, β-IFN: Beta-interferon, M: Male, F: Female GA: Glatiramer acetate Fg: Fingolimod DMF: Dimethyl fumarate NTZ:
Natalizumab TRF: Teriflunomide NT: No treatment

ceramide phosphocholine species were quantiﬁed using
internal standards by LC-MS/MS according to a previously
applied method [8]. Optimized multiple reaction
monitoring with positive electrospray ionization (ESI)
was used in ultrafast liquid chromatography (LC-20 AD
UFLC XR, Shimadzu Corporation, Kyoto, Japan) coupled
with MS-8040 triple quadrupole mass spectrometry
(Shimadzu Corporation). Chromatographic separations
were carried out using an HPLC column (XTerra 18, 2.1
× 50 mm, Waters, Milford, MA, USA). 7-Ketocholesterol
and cholestane-3β,5α,6β-triol were quantified with N,Ndimethylglycine derivatization in a modified application
of the LC-MS/MS method (MS-8040, Shimadzu
Corporation) [9]. Chromatographic separations were
done using a Symmetry C18 column (100 × 2.1 mm, 5 µm)
(Thermo Fisher Scientific, Waltham, MA, USA). Calcitriol
was also quantified by LC-MS/MS (MS-8040, Shimadzu
Corporation).
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3. Results
3.1. List of metabolites changed in pMS
Metabolites differing between pMS and healthy control
(Group C) samples were identified; most peaks were
eluted after 14 to 26 min. No marked difference was
observed between the chromatograms of Groups pMS and
C. The number of peaks detected with the optimum IPO
parameters was 2371. The remaining 907 peaks after data
processing [6] were examined for statistical differences
between the groups and the peaks showing a fold change
of >1.25 and p < 0.05 between Groups pMS and C (n =
349) are presented in a volcano plot in Figure 2. The
remaining list was processed via MetaboAnalyst 4.0 for
putative identification and the results were evaluated based
on a literature search to associate the metabolites with the
disease. Finally, 23 metabolites corresponding to 14 peaks
were found to be important (Table 2). Measurements
of sphingosine 1-phosphate, sphingophosphocholines,
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ceramides, 7-ketocholesterol, cholestane-3β,5α,6β-triol,
and calcitriol levels showed changes in the same direction
with untargeted data, although not differing significantly
between groups (Table 3).
The combination of the untargeted results with the
targeted results indicated increased levels of sphingosine1-phosphate, tyramine, 4-hydroxyphenylacetaldehyde,
pantetheine, 7-ketocholesterol, and cholestane-3β,5α,6βtriol and decreased levels of eicosanoids, sphingosine/3dehydrosphinganine, coproporphyrinogen III, (S)reticuline,
ketoleucine/3-methyl-2-oxovaleric
acid,
L-arginine/D-arginine, carnosine, 3α,7α,12α-trihydroxy5β-cholestan-26-al/calcitriol/sarsasapogenin, 20-hydroxyleukotriene E4, phosphoribosyl pyrophosphate, longchain (18–20) and very long-chain (22–24) ceramides,
and ceramide phosphocholines in Group pMS compared
to control samples (Group C).

3.2. PCA results
The PCA results showed that Group pMS and its
subgroups (i.e. Group pMS-T1 and Group pMS-T2) were
distinguishable from Group C (Figure 3a). The metabolite
profiles of Group pMS-T1 and Group pMS-T2 did not
differ statistically from Group pMS or from each other.
The individual samples of Group R, used to validate the
results, were found to constitute a subset of the cluster
formed by Group pMS, Group pMS-T1, and Group pMS-T2
(Figure 3b). This shows that the metabolite profiles of the
individual samples of Group R are represented by the
pooled samples of Group pMS. Group U samples were
statistically different from Group C; individual samples
U3, U4, U5, and U6 were outside of the cluster formed by
Groups pMS, pMS-T1, and pMS-T2 (Figure 3c).

Table 2. Putative identification of 14 peaks found to be statistically different and having fold changes of >1.25 between Group pMS and
Group C.
Peak #

KEGG Code

HMDB Code

Identity

C00233

HMDB0000695

Ketoleucine

C03465

HMDB0000491

3-Methyl-2-oxovaleric acid

2

C03765

HMDB0003767

4-Hydroxyphenylacetaldehyde

1.69

3

C00483

HMDB0000306

Tyramine

14.38

C00062

HMDB0000517

L-Arginine

C00792

HMDB0003416

D-Arginine

5

C00386

HMDB0000033

Carnosine

0.57

6

C00475

HMDB0000089

Cytidine

0.29

7

C00831

HMDB0003426

Pantetheine

2.38

C00319

HMDB0000252

Sphingosine

C02934

HMDB0001480

3-Dehydrosphinganine

C03263

HMDB0001261

Coproporphyrinogen III

C00427

HMDB0001381

Prostaglandin H2

C00584

HMDB0001220

Prostaglandin E2

C00696

HMDB0001403

Prostaglandin D2

C01312

HMDB0001335

Prostaglandin I2

C02198

HMDB0001452

Thromboxane A2

11

C02105

HMDB0003601

(S)-Reticuline

0.61

12

C00119

HMDB0000280

Phosphoribosyl pyrophosphate

0.30

13

C03577

HMDB0012639

20-Hydroxy-leukotriene E4

0.53

C01301

HMDB0003533

3α,7α,12α-Trihydroxy-5β-cholestan-26-al

C01673

HMDB0001903

Calcitriol

C03963

HMDB0030024

Sarsasapogenin

1

4

8
9

10

14

pMS/C
0.60

0.59

0.62
0.61

0.80

0.57
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Figure 2. Volcano plot showing the distribution of the detected metabolite peaks for groups pMS and
Group C. Gray dots: The metabolites examined in this study (fold change of >1.5, p < 0.05).

Table 3. Results of targeted analyses.
Group/metabolite

Sphingolipids (µg/mL)

Ceramides (ng/mL)

Metabolite

pMS/C

16:0 SM (d18:1/16:0)

0.86

18:0 SM (d18:1/18:0)

0.56

24:0 SM (d18:1/24:0)

0.68

S1P

1.35

C16 CER (d18:1/16:0)

1.14

C18 CER (d18:1/18:0)

0.73

C20 CER (d18:1/20:0)

0.69

C22 CER (d18:1/22:0)

0.75

C24 CER (d18:1/24:0)

0.94

Calcitriol (pg/mL)

0.86

7-ketocholesterol (7-KC) (ng/mL)

1.02

Cholestane-3β,5α,6β-triol (chol-triol) (ng/mL)

1.47

Abbreviations: 16:0 SM (d18:1/16:0), N-palmitoyl-D-erythro-sphingosylphosphorylcholine.
18:0 SM (d18:1/18:0), N-stearoyl-D-erythro-sphingosylphosphorylcholine.
24:0 SM (d18:1/24:0), N-lignoceroyl-D-erythro-sphingosylphosphorylcholine.
S1P, Sphingosine-1-phosphate.
C16 CER (d18:1/16:0), N-palmitoyl-D-erythro-sphingosine.
C18 CER (d18:1/18:0), N-stearoyl-D-erythro-sphingosine.
C20 CER (d18:1/20:0), N-arachidoyl-D-erythro-sphingosine.
C22 CER (d18:1/22:0), N-behenoyl-D-erythro-sphingosine.
C24 CER (d18:1/24:0), N-lignoceroyl-D-erythro-sphingosine.
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Figure 3. Principal component analysis graphs. Distribution of the metabolite profiles of the groups.
a) Groups pMS, pMS-T1, and pMS-T2 vs. Group C; b) Groups pMS, pMS-T1, pMS-T2, and R vs. Group
C; c) Groups pMS, pMS-T1, pMS-T2, and U vs. Group C.

4. Discussion
Demyelinating diseases constitute a large group
including MS, neuromyelitis optica, acute disseminated
encephalomyelitis, and neuromyelitis optica spectrum
disorder (NMOSD), and their treatment approaches differ
considerably. However, distinctions within this spectrum
can be difficult and certain cases do not receive a definite
diagnosis by clinical and imaging findings at the time of the
initial episode. Therefore, biomarkers reflecting metabolic
status are being investigated to assist in clinical decisions;
they can also clarify pathophysiology.
4.1. Proposed biomarker set based on results
Previous plasma metabolic profiling by nuclear magnetic
resonance spectroscopy and PCA graph analysis for
108 individuals with demyelinating disorders (34 with
relapsing-remitting MS, 54 with AQP4-Ab NMOSD, and 20
with MOG-Ab disease) suggested that relapsing-remitting
MS could be differentiated from aquaporin-4 IgG-positive

NMOSD through various combinations of scyllo-inositol,
myo-inositol, lipoprotein particles, histidine, glucose,
lactate, alanine, formate, and leucine that differed between
the groups [10]. Another study showed that higher levels
of myoinositol and formate in relapsing-remitting MS
allowed differentiation from antibody-negative NMOSD
[11]. Scyllo-inositol and myo-inositol are metabolites of
sphingosine metabolism. In our study, plasma sphingosine
was decreased and sphingosine-1-phosphate (S1P) was
elevated in Group pMS compared to Group C. In MS,
sphingolipids released from damaged myelin can be broken
down to sphingosine, which then turns into S1P in states
of intense inflammation or immune dysregulation [12].
MS-associated proinﬂammatory cytokines can activate
the sphingomyelin cycle in oligodendrocytes. Studies
found higher S1P levels in the CSF and lower sphingosine
and dihydrosphingosine levels in the blood of MS patients
compared to a control group [13].
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Ceramides are mainly generated by the hydrolysis of
sphingomyelin, but they are also synthesized de novo and
converted to complex sphingolipids. They take part in the
myelin structure and signal transduction, and they have
bioactive roles in inflammation and neurodegeneration.
Group pMS had reduced long-chain (18–20) and very
long-chain (22–24) ceramides, but not C16 ceramide,
and reduced 16–24 sphingomyelins (ceramide
phosphocholine) compared to Group C. Kurz et al., in a
cohort study that included 72 MS patients and 25 healthy
controls, demonstrated downregulated C24 ceramide in
the leukocytes of MS patients and upregulated C16 and
C24:1 ceramides in control plasma [14]. Interestingly,
they found that C16-LacCer was downregulated in MS
patients compared to healthy controls; likewise, only
C16 ceramide was found to be higher in pMS patients
in our study. Therefore, low levels of long-chain (18–
20) and very long-chain (22–24) ceramides, 16–24
sphingomyelins, and sphingosine and high levels of S1P
suggest both myelin alteration or degradation and the
role of sphingosine and ceramide metabolism in the
pathophysiology of MS.
Tyramine is a naturally occurring trace amine derived
from tyrosine. It was significantly increased in Group
pMS (Group pMS/Group C ratio: 14.38) in the present
study, and 4-hydroxyphenylacetaldehyde, produced from
tyramine by monoamine oxidase and from L-tyrosine
by activated phagocytes, was also elevated by 1.69-fold.
Tyramine promotes the release and actions of adrenergic
transmitters, which act on immune and neural cells, as
reported in cases of MS [15].
Pantetheine, a cysteamine amide analog of pantothenic
acid (vitamin B5), was increased by 2.38-fold in Group
pMS. Pantetheine is an intermediate in the biosynthesis
of coenzyme A, which has an important role in energy
metabolism, especially in mitochondrial reactions; its
deficiency can potentiate oxidative stress, inflammation,
and demyelination [16]. In MS patients, the disturbance
of pyruvate metabolism and mitochondrial reactions
can increase extramitochondrial glucose and anaerobic
metabolites [17].
Prostaglandins or thromboxane A2 are involved in
many inflammatory disorders. The main enzyme in their
synthesis from arachidonic acid is 5-lipoxygenase, which is
upregulated in peripheral blood cells of MS patients during
relapse. The action of 5-lipoxygenase varies according to
its intracellular localization; 5-lipoxygenase on the nuclear
membrane of neutrophils, mast cells, and macrophages
promote the synthesis of proinflammatory leukotriene B4
while cytoplasmic 5-lipoxygenase favors the synthesis of
the regulating mediator lipoxin A4 in macrophages [18].
Likewise, some prostaglandins are pro- and others are
antiinflammatory. Prostaglandin-E1 and D2 have been
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implicated in the treatment of MS, both within the action
of certain drugs and as separate therapeutic options [19].
Thromboxane production has been studied in progressive
but not relapsing-remitting MS. Its detection in plasma
indicates the activation of endothelia or monocytes in
an inflammatory state [20]. The lower levels observed in
Group pMS compared to Group C in the present study
may imply the role of eicosanoids in pMS, but this needs
verification by targeted measurements of individual
eicosanoids.
(S)-Reticuline, an endogenous precursor of morphine,
was lower in Group pMS. Morphine in human tissue is
considered to be of exogenous origin, but recent studies
have shown that human cells can produce morphine in
nanomolar ranges and (S)-reticuline is an important
precursor [21]. Thus, the decreased (S)-reticuline in
Group pMS may imply decreased synthesis of morphine
at the metabolite level. Morphine has immunomodulatory
effects in humans through brain-like-opioid receptors
expressed on lymphocytes [22]. The effect of endogenous
morphine in the immunopathogenesis of MS should be
explored further.
Coproporphyrinogen III, a porphyrin metabolite
arising from heme synthesis, was lower in Group pMS
compared to control samples, which may reflect diminished
synthesis. Heme is found in a number of hemoproteins
such as hemoglobin, myoglobin, cytochromes,
catalases, heme peroxidase, and endothelial nitric oxide
synthase (NOS). Free hemoglobin can contribute to MS
pathogenesis by damaging the blood-brain barrier and
myelin. However, hemoglobin in neural cells is considered
to be neuroprotective [23]. An important heme-containing
complex is the ubiquinone-cytochrome c reductase in the
mitochondria; reduced function of this complex may result
in mitochondrial dysfunction [24]. Therefore, reduced
heme synthesis may contribute to cellular damage.
Ketoleucine and 3-methyl-2-oxovaleric acid are
abnormal metabolites arising from the incomplete
breakdown of branched-chain amino acids. Lower levels
were detected in Group pMS compared to controls. Noga
et al., in a rat model of MS, observed that arginine, alanine,
and branched amino acids were low at the time of onset
and increased at the peak of the disease [25]. As branchedchain amino acids are a source of pyruvate for energy
metabolism or de novo synthesis of macromolecules,
their reduction may suggest utilization within neural and
immune cells in early-stage pMS [26].
The peaks of D- and L-arginine were significantly
smaller in Group pMS (Group pMS/Group C ratio:
0.59). Arginine is converted by NOS to NO, which can be
neuroprotective or neurotoxic depending on the degree of
injury, cellular redox status, location, and concentration
of synthesis. NO is associated with oligodendrocyte
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dysfunction in demyelinating diseases [27]. NO synthesis
is stimulated by activated microglia and Th17 cells and it
may be increased in the tissues, CSF, and plasma of MS
patients. Therefore, reduction of arginine may be expected
[28]. A study comparing the plasma metabolomics of 28
patients with relapsing-remitting MS and 18 unaffected
individuals found lower concentrations of arginine in the
MS group, which also correlated with certain MRI findings
[29].
Carnosine is a naturally distributed dipeptide composed
of histidine and β-alanine whose modulation of free radical
production results in antioxidant, antiinflammatory,
antiapoptotic, and particularly neuroprotective properties
[30]. In Group pMS in the present study, the low level
of carnosine (Group pMS/Group C ratio: 0.57) might
indicate the contribution of similar mechanisms.
Diminished levels of 3α,7α,12α-trihydroxy-5βcholestan-26-al, an intermediate in bile acid biosynthesis,
and elevated levels of 7-ketocholesterol and cholestane3β,5α,6β-triol were found in Group pMS. Bhargava et al.
reported that MS and pMS patients had lower levels of bile
acid metabolites [31]. Bile acids may be neuroprotective
and antiinflammatory in neurodegenerative disorders
as enzymes of the alternative bile acid synthesis pathway
are expressed in the CNS. Circulating bile acids can act
on receptors expressed on astrocytes and macrophage/
microglia, and supplementation was found to be of benefit
in experimental autoimmune encephalomyelitis [31, 32].
Therefore, oxysterols might be involved in pMS within
inflammatory pathways.
Calcitriol, the physiologically active form of vitamin D,
is known to play a preventive role in MS [33]. Numerous
studies on sunlight exposure, latitude, and diet support a
correlation between serum concentrations of vitamin D
and disease severity [34]. As expected, our pMS patients
had lower calcitriol levels as confirmed by targeted analysis
(Group pMS/Group C calcitriol ratio: 0.86).
Decreased phosphoribosyl pyrophosphate in Group
pMS implies inadequate transfer of phosphate groups
in the biosynthesis of histidine, tryptophan, and purinepyrimidine nucleotides. Tryptophan and its metabolites
affect immune response in MS; their levels were low
in adult MS patients compared to healthy subjects.
In addition, higher serum levels of tryptophan were
associated with a lower risk of pMS [35]. Histidine, another
amino acid reported to be neuroprotective, was also low
in serum samples from MS patients [36]. Purinergic
signals play key roles in myelination, neuroprotection,
and neurodegeneration, and they have been implicated
in neurodegenerative and neuroinflammatory diseases
[37]. Reduced levels of tryptophan, histidine, purine,
and pyrimidine may take part in neuroprotection and
inflammatory regulation in pMS.

Cytidine is a pyrimidine incorporated into nucleic
acids and it can serve as a substrate for the salvage pathway
of pyrimidine nucleotide synthesis. Cytidine triphosphate
is involved in the biosynthesis of phosphatidylcholine
and phosphatidylethanolamine, the most abundant
phosphatides in the brain. Together with studies on
phospholipids in MS, low cytidine levels in Group pMS
in the present study support a pathogenetic role of
phosphatidylcholine [38].
4.2. PCA results for monitoring pMS
The PCA results showed that Group pMS and its subgroups
(pMS-T1 and pMS-T2) were distinguishable from Group C.
Individual random samples (Group R) used to validate the
results fell within the cluster formed by Groups pMS, pMS-T1,
and pMS-T2. As expected, Group U samples differed from
those of Group C. Upon follow-up, U3, U5, and U6 were
diagnosed with pMS; U1 was diagnosed with antimyelin
oligodendrocyte glycoprotein (MOG) disease; U2 retained
the diagnosis of clinically isolated syndrome (CIS); and
U4 was diagnosed with parainfectious myelitis, indicating
classification errors in the cases of U3, U4, and U6. The
PCA graphs (Figure 3) illustrate this approach, as individual
random samples (Group R) could easily be distinguished
from control samples, unclassified samples that turned out
to be non-MS (U1, U2) could be categorized correctly, and
U3, U4, U5, and U6 were erroneously categorized outside of
the pMS group. Although the random samples (Group R)
corresponded with the cluster of Group pMS, U3, U4, U5,
and U6 did not meet the diagnostic criteria of pMS while
the analysis was being performed. This suggests that even if
metabolomic analysis reflects the actual conditions clearly,
it has some limitations in suggesting further predictions
for the diagnosis of pMS. Another important point
illustrated by the PCA graphs was the similar distribution
of pMS-T1 and pMS-T2, suggesting that clinical attacks
and β-IFN treatment make no detectable differences at this
metabolomic level.
The pathogenesis of MS involves numerous
inflammatory reactions that have been studied with a
variety of methods. To date, however, there is no candidate
biomarker that can point to the disease mechanism in MS.
This first untargeted metabolomic study of pMS has
indicated pathways involving sphingolipid, branchedchain amino acid, and bile acid metabolism along with
mitochondrial dysfunction and oxidative stress.
The use of pooled samples rather than individual
samples minimizes individual metabolomic changes and
the metabolites found to differ between pooled pMS and
control groups are those directly related to pMS. This type
of analysis is complemented by comparison of individual
samples from subjects with and without pMS, allowing the
evaluation of metabolites that differ in individual random
samples.
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The limitations of this study include the sizes of
Group pMS and its subgroups. Although these were
comparable to group sizes of the previous studies cited
above and acceptable considering the prevalence of pMS,
further studies with larger series reflecting various stages
of the disease are needed. The sizes of the other groups
were also limited. In particular, expanding the category
of “unclassified demyelinating diseases” is important for
clinical applications of this method. The “unclassified”
group was named as such at the time of plasma sampling;
some of those individuals received diagnoses of CIS,
isolated myelitis, and MOG Ab-related disease upon
follow-up. The search for related biomarkers specifically
aims to avoid diagnostic delays such as these. The duration
of disease was short for most of our patients, as can be
expected in cases of pMS. Although a limitation in general,
this can also be an advantage, as the chronicity and severity
of a clinical condition can affect metabolomics and our
findings may reflect the early stages, where inflammation
is prominent and neurodegeneration is mild. The
examination of changes that develop over the course of the
disease through longitudinal studies and correlations of
metabolomic findings with MRI and Expanded Disability
Status Scale (EDSS) results would be of scientific and
clinical interest. Likewise, larger numbers of patients with
other CNS demyelinating disorders and pMS patients
receiving various disease-modifying treatments need to
be compared. As our study was primarily designed for
large-scale metabolomic screening, targeted analyses were
very limited; in the future, such studies should include
all metabolites of interest. On the other hand, important
strengths of this study include the demonstration of

metabolomic changes allowing clear separation between
the definite pMS and control groups, and the findings for
the test group of “unclassified” demyelinating diseases
being similar to those of Group pMS. These initial
results obtained from untargeted metabolomic analysis
are encouraging for further research investigating the
application of these methods in the diagnosis, differential
diagnosis, and prediction of pMS.
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